Ivermectin inhibits epithelial-to-mesenchymal transition via Wnt signaling in endocrine-resistant breast cancer cells (2025)

Peer-Reviewed Study · Rujimongkon K; Adchariyasakulchai P; Meeprasertskul P; Ketchart W · 2025

Rujimongkon K et al., 2025: In vitro study in tamoxifen- and fulvestrant-resistant MCF-7 sublines reporting that ivermectin inhibits proliferation, invasion and EMT-related Wnt signalling at low micromolar IC50 values.

The findings indicated that IVM's half-maximum inhibitory concentration (IC50) inhibited MCF-7/LCC2 and MCF-7/LCC9 at 9.35 and 9.06 µM, respectively, within 24 h of treatment.

n/a (HTML full text)

Rujimongkon K et al., 2025: In vitro study in tamoxifen- and fulvestrant-resistant MCF-7 sublines reporting that ivermectin inhibits proliferation, invasion and EMT-related Wnt signalling at low micromolar IC50 values. Study type: cell lines only (MCF-7/LCC2, MCF-7/LCC9). N: n/a. Country: Thailand (Chulalongkorn University, Bangkok). Dose: IC50 9.06-9.35 uM in vitro, 24 h; no in vivo arm. Funder: not stated in the record. Declared COI: 'The authors have declared that no competing interests exist.' Comparator: vehicle-treated cells. Note the active concentrations are low micromolar, above usual human plasma exposure. Study type: lab.